
- Remove this product from my favorite's list.
- Add this product to my list of favorites.
Products
Newsletter
![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
Background: EPHA2 belongs to a unique family of receptor tyrosine kinase that play critical roles in embryonic patterning, neuronal targeting, and vascular development during normal embryogenesis. EPH receptors bind promiscuously membrane-bound ephrin-ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. The EPHA2 regulates cell adhesion and differentiation through DSG1/desmoglein-1 and inhibition of the ERK1/ERK2 (MAPK3/MAPK1, respectively) signaling pathway.
Human EPHA2 (Ephrin type-A receptor 2), amino acids L585-I976 (tyrosine kinase domain), recombinant and active enzyme, N-terminal GST-HIS6 fusion protein with a 3C cleavage site
Theoretical MW: 73.691 kDa (fusion protein)
Expression system: Baculovirus infected Sf9 cells
Purification: One-step affinity purification using GSH-agarose
Storage buffer: 50 mM Tris-HCl, pH 8.0; 100 mM NaCl, 5 mM DTT, 4 mM reduced glutathione, 20% glycerol
Protein concentration: 0.505 mg/ml (Bradford method using BSA as standard protein)
Method for determination of Km value & specific activity: Filter binding assay MAFC membrane
Specific activity: 30,000 pmol/mg x min
Entrez Gene ID: 1969
UniProtKB: P29317
Ordering information: shipped on dry ice
Ireton RC1, Chen J."EphA2 receptor tyrosine kinase as a promising target for cancer therapeutics."Curr Cancer Drug Targets. 5(3):149-57.
Miao H., Burnett E., Kinch M., Simon E., Wang B.(2000)"Activation of EphA2 kinase suppresses integrin function and causes focal-adhesion-kinase dephosphorylation."Nat. Cell Biol. 2:62-69
Miao H., Li D.Q., Mukherjee A., Guo H., Petty A., Cutter J., Basilion J.P., Sedor J., Wu J., Danielpour D., Sloan A.E., Cohen M.L., Wang B.(2009)"EphA2 mediates ligand-dependent inhibition and ligand-independent promotion of cell migration and invasion via a reciprocal regulatory loop with Akt."Cancer Cell 16:9-20
Welcome Login
Contact us
Follow us